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Objectives: Report baseline patient characteristics of the CAMPOS study, which 
is evaluating the PMO care map in Swiss clinical practice. MethOds: Between 
June 2012„ŸMay 2013, specialist osteoporosis centers operating a DXA machine 
enrolled women diagnosed with PMO who initiated intravenous (IV) ibandronate 
or zolendronate, or subcutaneous (SC) denosumab (index date) within 6 months 
prior to center initiation. Study outcomes are recorded at index date (baseline) 
and any visit in the 24-month observation period thereafter, as available from rou-
tine practice. Results: Twenty-one centers, mainly in urban regions (81%), of a 
non-academic nature (76%), and specializing in rheumatology (71%), recruited 275 
women. Two-hundred-sixty-three met the inclusion criteria and were included in 
this baseline analysis; 180 (68%) of these received follow-up care at the specialist 
center and 83 (32%) were referred back to general practice. At baseline, mean (SD) 
age was 70.9 (9.7) years and mean time since diagnosis 5.4 (5.4) years (n= 248). The 
following diagnostic parameters and risk factors were assessed at the time of PMO 
diagnosis: prior osteoporotic fracture, 258 [94%] patients, with 60% reporting this 
risk factor; DXA bone mineral density (BMD) scan, 255 (97%) patients (hip and either 
lumbar spine or forearm BMD measured in 231 [88%] patients), mean (SD) BMD 
T-scores at the femoral neck and lumbar spine -2.34 (0.79; n= 230) and -2.89 (1.28; 
n= 232), respectively; calcium and vitamin D status, 260 (99%) patients; fracture 
history, 258 [98%] patients. cOnclusiOns: In the current study, prevalent frac-
tures were assessed in almost all women initiating IV ibandronate or zolendronate, 
or SC denosumab, and the majority reported at least one prior fracture. Calcium 
and vitamin D status, DXA BMD scans and/or fracture history were also routinely 
assessed at PMO diagnosis.
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Objectives: Osteoarthritis (OA) and the demand for OA care are increasing with 
the aging population. Policy-makers seek to identify policies to sustainably manage 
this growing demand, yet envisioning the short- and long-term effects of policy 
options is difficult within chronic care. We aimed to develop a decision-support 
tool enabling policy-makers to explore policies and their effects. MethOds: We 
developed a system dynamics (SD) simulation of patient flow across the continuum 
of OA care in Alberta: from self-directed to primary and specialist care, through 
surgical interventions, post-surgical follow-up and subsequent re-operations. The 
simulation was developed using SD modeling principles and an iterative, integrated 
knowledge translation process, including multiple workshops with clinicians and 
administrators to define the problem, system boundaries and current patient flow. 
The resulting simulation was populated with data extracted from administrative 
databases (e. g. physician claims, inpatient records). Results: The model yields 
patient population, OA care resource requirements and associated cost results at 
each stage of care over 10 years by region and patient characteristics (e. g. sex). If 
current practices continue, annual hip and knee replacement surgery volumes are 
estimated to increase by more than 5,000 between 2015 and 2025. If a 14 week surgi-
cal wait-time is implemented in 2015, 600 additional surgeries must be performed 
in the first year to “catch-up” on the existing surgical queue, yet long-term surgery 
rates are similar to those without the wait-time target. The costs of the additional 
surgeries are partly offset by the savings achieved by fewer patients requiring care 
while awaiting surgery. cOnclusiOns: This simulation can be used as a decision-
support tool to estimate changes in patient populations, resource requirements 
and costs over time that may result from various OA management scenarios. Such 
results can equip policy makers with additional evidence to make more informed 
OA care policy decisions.
PMS95
the uSe of CliniCal data rePoSitory for the eStaBliShMent of an 
oSteoPoroSiS regiStry in a large health organization in iSrael: 
ePideMiologiC and PharMaePideMiologiC findingS
Goldshtein I.1, Shalev V.2, Chodick G.3, Chandler J.4, Martin Nguyen A.5, ish Shalom S.6
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Medical Division, Maccabi Healthcare Services, Tel 
Aviv, Israel, 3Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel, 4Merck, North 
Wales, PA, USA, 5Merck, North wales, PA, USA, 6Technion university, Haifa, Israel
Objectives: Osteoporosis is an important public health issue due to its rising preva-
lence and excess morbidity and mortality among this population. The present study 
aimed to demonstrate the use of clinical data repository in Israel’s second largest 
health organization (Maccabi Healthcare Services) to establish a registry of osteopo-
rosis patients and assess its early findings with respect to the epidemiology and bur-
den of the disease, high risk populations, and quality of care. MethOds: Included 
in the registry are patients with history of osteoporosis diagnosis, typical fractures 
(e. g. closed fractures of proximal femur, vertebral, Colles’ and proximal humerus) 
and or purchases of relevant medications, documented since 2000. In addition, we 
included patients with low bone density from over 140,000 measurements, using an 
Objectives: To estimate future scenarios of utilization of knee arthroplasty (KA) 
revision in the Spanish National Health System at the short and long term and its 
impact on primary KA utilization. MethOds: A discrete event simulation model 
was built to represent the utilization of KA for 20 years (2011–2031) in the Spanish 
National Health System, especially the burden of KA revision according to differ-
ent scenarios of utilization and protheses survival. Data on KA utilization from 
1997 to 2011 was obtained from the Spanish Minimum Data Set. Three scenarios 
of future utilization of primary KA were estimated: 1) fixed number since 2011; 2) 
fixed age and sex adjusted rates since 2011; and 3) projection using a linear regres-
sion model. These three scenarios were combined with two prostheses survival 
functions L) from a study including primary KA from 1995 to 2000; and H) from 
the Catalan Registry of Arthroplasty, including primary KA from 2005 to 2013. The 
model was programmed using ARENA. The simulation results were analyzed at the 
short (2015) and long-term (2030). Results: Variations in the number of revisions 
depended on both the primary utilization rate and the survival function applied, 
ranging from 8.3% to 31.6% increase at the short-term and from 38.3% to 176.9% 
at the long term, percentages corresponding to the combinations of scenario 1 
(low primary utilization rate) and survival function H (better survival) versus sce-
nario 3 (high primary utilization rate) and survival function L (worse survival), 
respectively. The prediction of increase on overall surgeries ranged from 0.1% to 
22.3% at the short-term and from 3.7% to 98.2% at the long-term. cOnclusiOns: 
Projections of the burden of knee arthroplasty provide a quantitative basis for 
future policy decisions relating to concentration of high complexity procedures, 
the number of orthopaedic surgeons required to perform these procedures and 
the number of resources needed.
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Objectives: Cachexia is a medical syndrome associated with several chronic 
health conditions including many cancers, COPD, HIV, and kidney disease. 
Cachexia is a wasting type syndrome characterized as a loss in body mass or 
metabolic dysfunction. The loss in mass is associated with decreases in strength 
and functional capacity. Currently there is little research into cachexia and our 
objective is to characterize cachexia patients, their health care utilization and 
costs. MethOds: For this study we utilized one year (2009) of the Nationwide 
Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% 
sample of hospitals within the United States. We grouped cachexia individuals 
by primary or secondary diagnosis and then compared those with cachexia to all 
others in terms of length of stay (LOS) and total cost. Finally we looked into factor 
predicting increased LOS using a negative binomial model. Results: We esti-
mated US prevalence for cachexia related admissions at 161,898 cases. Cachexia 
patients were older with an average age of 67.95 versus 48.10 in their non-cachexia 
peers. Hospitalizations associated with cachexia had an increased LOS compared 
to non-cachexia patients (6 days versus 3) with average costs per stay $4,641.30 
greater. Differences were seen in loss of function (LOF) with cachexia patients 
mostly in the major LOF category (52.60%) whereas non-cachexia patients were 
spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%). 
Significant positive predictors of increased LOS among cachexia patients included 
urban hospital (IRR= 1.21 non-teaching urban, IRR= 1.23 teaching urban), having 
either major (IRR= 1.41) or extreme (IRR= 2.64) LOF, and having a primary diagnosis 
of pneumonia (IRR= 1.15). cOnclusiOns: Cachexia is a diverse syndrome associ-
ated with a number of chronic diseases. We have characterized cachexia and seen 
it associated with increased length of stay, increased cost, and more severe loss 
of function compared to those without cachexia.
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Objectives: To describe baseline characteristics and changes in BMD T-scores at 
1 year, in postmenopausal women with OP receiving 2 denosumab injections in 
routine clinical practice in Bulgaria. MethOds: This retrospective observational 
study, conducted in 11 specialist (endocrinology or rheumatology) practices scat-
tered geographically across Bulgaria, included postmenopausal women ≥ 50 years 
old with a clinical diagnosis of OP, who initiated denosumab 60 mg Q6M on or after 
Oct 2011 (regulatory approval of denosumab in Bulgaria) and received a follow-up 
injection within 7 months (until Aug 2013). All study outcomes were recorded as per 
routine clinical practice/reimbursement requirements, with BMD T-scores recorded 
(at ≥ 1 site) at first denosumab injection (baseline) and 1-year follow-up. Descriptive 
statistics were conducted. Results: 222 women met the inclusion criteria with a 
mean (SD) age of 64.2 (±8.54) years; approximately half (49.5%) were < 65 years old 
and13.1% ≥ 75 years. Mean (SD) age at menopause was 48.1 (±3.98) years. 26.6% 
reported a prior fragility fracture, with vertebral the most common site (71.2%) 
followed by hip (6.8%) and other sites (32.2%, excluding hip). At baseline, 2.7% were 
receiving vitamin D only, 5.9% calcium supplements only and 35.1% both; 31.5% had 
received prior OP therapy. At baseline, mean (SD) BMD T-score was -3.2 (±0.63) at 
the lumbar spine (LS; n= 189), -2.3 (±0.81) at the total hip (TH; n= 75) and -2.7 (±0.71) 
at the femoral neck (FN; n= 137). At 1-year follow-up, all women had BMD assessed 
at ≥ 1 site; T-scores increased to -2.7 (±0.57) at the LS (n= 187), -2.1 (±0.91) at the TH 
(n= 65) and -2.4 (±0.68) at the FN (n= 123). cOnclusiOns: Postmenopausal women 
with OP receiving 2 denosumab injections in Bulgarian clinical practice had a mean 
age of 64.2 years and experienced improved mean BMD T-scores at the LS, TH, and 
FN after 1 year. Study funded by Amgen.
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Objectives: The purpose of this analysis was to estimate how higher persistence 
in RRMS patients treated with interferon beta 1-a and its electronic injection device 
(Rebismart®) affects the rate of escalation to 2nd line therapies. MethOds: A 2-year, 
decision-analytic model was developed to track a hypothetical cohort of 1,000 RRMS 
patients initiating treatment with either interferon beta 1-a and Rebismart® or 
another 1st line self-injectable disease modifying drug (DMD). The model calculated 
the expected probability of escalating to 2nd line therapy, which was defined as either 
Gilenya® or Tysabri®. Persistence curves were estimated from a real-world dataset 
collected from the UK NHS where at 2 years Rebismart® users had 83% persistence vs. 
60% in non- Rebismart® users. A market research study was utilized to determine the 
treatment pathways for non-persistent patients, where 39% transitioned to another 
1st line DMD; 21% abandoned therapy and 40% escalated to 2nd line therapies. One-
way sensitivity analyses (OWSAs) varied the probability of non-persistent 1st line 
patients escalating to 2nd line therapies from 5% to 100%. Results: The model esti-
mated that over two years 5.4% of patients on the Rebismart® device are expected to 
escalate to 2nd line therapy, while 18.3% of patients that initiated treatment on other 
DMDs are expected to escalate. At the lower bound of the OWSA, 0.68% of patients are 
expected to escalate on Rebismart®, vs. 2.3%; while at the upper bound of the OWSA, 
13.3% of Rebismart® patients are expected to escalate vs. 42.7%. cOnclusiOns: 
Higher persistence rates in RRMS patients initiating treatment with interferon beta 
1-a and the Rebismart® electronic device are expected to result in fewer escalations 
to 2nd line therapies relative to other self-injectable DMDs.
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Objectives: To assess the relative efficacy and safety of modified-release levodopa 
(IPX066), controlled-release levodopa and add-on therapy to immediate-release 
levodopa (including dopamine agonists, monoamine oxidase-B inhibitors (MAOBI), 
and catechol-O-methyl transferase inhibitors (COMTI)) using network meta-analy-
sis (NMA). MethOds: A systematic literature search was conducted in MEDLINE, 
MEDLINE In-Process, EMBASE, Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, DARE and HTA. A random effects NMA was used 
to determine the relative efficacy and safety of treatments on off-time reduction, 
three Unified Parkinson’s Disease Rating Scale (UPDRS) scores, patient withdrawals, 
and six adverse events in WinBUGS. An additional analysis was conducted to assess 
treatment class effects. Node-splitting approach was used to assess the assumption of 
consistency when direct and indirect evidence was combined. Results: Forty-three 
trials with 9,453 patients were identified. Immediate-release levodopa plus prami-
pexole produced the greatest reduction in off-time relative to immediate-release 
levodopa plus placebo (-1.71 hours a day; 95% CrI: -2.11, -1.35), followed by IPX066 
(-1.40; 95% CrI: -2.19, -0.67). The greatest improvement on UPDRS ADL score was given 
by add-on ropinirole (-2.33 points; 95% CrI: -3.53, -1.06); on UPDRS motor and total 
score was given by add-on pramipexole (-5.88 points; 95% CrI: -7.22, -4.63 and -10.09 
points; 95% CrI: -13.75, -6.56, respectively). Dyskinesia was increased with IPX066 and 
adjuvant therapy classes except for MAOBIs. Patient withdrawals were also increased 
with IPX066 and controlled-release levodopa. cOnclusiOns: The NMA showed that 
all treatments except controlled-release levodopa were associated with a statistically 
significant reduction in off-time. Dopamine agonist class as adjunctive to levodopa 
therapy had the greatest reduction. IPX066 was broadly comparable with add-on 
dopamine agonists on off-time reduction, and comparable with add-on MAOBIs and 
COMTIs on UPDRS scores. However, the treatments were associated with an increase 
in the risk of having dopaminergic side effects, particularly dyskinesia.
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Objectives: To describe caregivers’ Health Related Quality of Life (HRQoL), burden, 
anxiety and depression and their relation with patients’ symptoms in Parkinson 
disease (PD). MethOds: A descriptive, observational, longitudinal design in PD 
patients and their caregivers of ELEP study (2006-2010), in Spain. Information 
collected during 3 month per year for 4 years, included sociodemographic char-
acteristics, motor symptoms (SCOPA-Motor) and HRQoL (EQ-5D: index and VAS) 
from PD patients and burden (Zarit’s CBI), anxiety (HADS-A), depression (HADS-D) 
and HRQoL from their caregivers. Linear mixed models were performed to assess 
the relation between caregivers’ burden with the patients’ motor symptoms and 
HRQoL. Results: 174 PD patients, mean age: 63±11, 50% male, PD duration: 8±6 
years; 173 caregivers, 66.5% female, mean number of years taking care of patients: 
6±5, were included. Patients’ SCOPA-Motor varied from 39.3±8.4 in year 1 to 42.5±9.5 
in year 4; EQ-5D index and VAS from 0.7±0.3 and 63.7±20.3 to 0.6±0.3 and 60.3±17.9, 
respectively. Caregivers’ ZCBI varied from 17.6±12.6 to 20.0±14.8; EQ-5D index 
remained unchanged at 0.8±0.2, while VAS varied from 73.7±18.6 to 75.0±16.2; 
HADS-D scores changed between 4.0±3.7 and 4.4±4.3, and HADS-A from 6.7± 3.8 
to 6.9±4.3. Linear mixed models revealed that caregivers’ anxiety and depression 
negatively influenced their own perception of disease burden [HADS-A, Estimated 
coefficient (EC): 1.02 (SE: 0.15), p< 0.000; HADS-D, EC: 1.19 (SE: 0.17), p< 0.000]. Patients’ 
motor symptoms predicted worse caregiver burden [SCOPA-Motor EC: 0.22 (SE: 0.09), 
p= 0.014]. Decline in patients HRQoL implied a higher caregiver burden [EQ-5D index 
EC: -5.56 (SE: 2.70), p< 0.041]. cOnclusiOns: PD patients’ moderate motor symp-
toms and fair HRQoL worsened over time as did caregivers’ anxiety and disease 
automated Optical Character Recognition (OCR) system. Patients younger than 18 
years of age, diagnosed with Paget’s disease or purchasing pamidronic or zoledrnic 
acid due to cancer were excluded. Registry entry date was defined as the first medi-
cal event consistent with any of inclusion and all exclusion criteria. Results: We 
identified 118,141 patients with osteoporosis, with a point prevalence of 19% in 2013 
among members aged 50+, and an average incidence of approximately 6,300 cases 
a year. Average age at registry entry was 61 y/o for women and 66 y/o for men. 66% 
of the patients had more than one qualifying criteria. 28% of the registry patients 
were never treated. cOnclusiOns: The methods and results described may provide 
a model for the development of an important tool to assess the substantial burden 
of osteoporosis and to monitor the quality of care over time.
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Objectives: The use of PPIs to reduce the risk of upper GI events caused by 
NSAIDs is well documented. The aim of this study was to understand whether 
newly diagnosed patients with OA, RA or AS not previously exposed to PPIs, receive 
a gastro-protectant with their NSAID treatment at initiation or follow up in a 
primary care setting. MethOds: We analyzed data from primary care Electronic 
Medical Records in Ontario, Canada. Patients ≥ 18 years, who were new users of 
NSAIDs, NSAID plus a PPI, a fixed combination of diclofenac and misoprostol, or 
Celecoxib between January 1st 2010 and May 31st 2012 were selected. Patients must 
have had a diagnosis for OA, RA, or AS within 6 months of treatment initiation, 
but no diagnosis in the year prior. Patients were followed for 6 months to assess 
for subsequent PPI prescription. Patients prescribed a PPI in the last 12 months 
were excluded. Results were compared to Canadian longitudinal pharmacy 
data. Results: There were 692 patients included, 56% females and a mean age of 
44 years (SD 15). Naproxen was the most commonly used treatment (41%), followed 
by diclofenac (26%), celecoxib (14%) and diclofenac with misoprostol (19%). PPIs 
were added at treatment initiation in 2.5% of naproxen patients, 1.7% of diclofenac 
patients and 3.7% of patients with fixed combination of diclofenac and misopros-
tol. PPI prescription patterns within 6 months were similar and consistent with 
patterns observed in the Canadian longitudinal pharmacy data. cOnclusiOns: 
Results suggest that primary care physicians in Canada do not prescribe PPIs 
with NSAIDs at or within 6 months after NSAID initiation. Limitations include 
small sample size and young patient cohort. Further studies are required to bet-
ter understand the impact of low PPI concomitant use with NSAIDs, especially in 
older patients or those at a higher risk of GI events.
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Objectives: This study aimed to investigate and compare the gastrointestinal (GI) 
risk factors and treatment patterns of rheumatoid arthritis (RA) and osteoarthritis 
(OA) patients in real clinical practice of Korea. MethOds: This was a nationwide, 
cross-sectional study of patients taking non-steroidal anti-inflammatory drugs 
(NSAID, either non-selective or selective COX-2 inhibitor (COX2i)) from 20 hospitals 
between December 2012 and September 2013. Total 1,896 patients who were ≥ 20 
years old (RA: 981 OA: 915) and were taking NSAID at least 1 month were enrolled. 
Data were collected through medical chart review and patients survey. The GI risk 
factors included NSAID duration (≥ 3 months), high-dose of NSIAD use, drinking, 
smoking, comorbid disease, aspirin use, anticoagulant (warfarin) use, steroid use, 
Helicobacter pylori infection, experience of GI event (i. e. GI bleeding or ulcer). The 
treatment patterns were identified as non-selective NSAID (ns-NSAID) or COX2i 
with/without gastroprotective agents respectively. Results: In RA, proportion of 
patients taking NSAID≥ 3 months, smoker and steroid users were higher than in 
OA patients (p< . 0001). In OA, proportion of patients who have comorbid disease 
and take aspirin were higher than in RA patients (p< . 0001). The rest of the GI 
risk factors were present as a similar proportion in both groups. The percentage 
of treatment with COX2i (RA: 54.3% vs OA: 44.2%, p< . 001) and gastroprotective 
agents (RA: 83.0% vs OA: 78.3%, p= . 009) in RA patients was higher than that in 
OA patients. In older aged patients (age≥ 60) in both groups, there was tendency 
to get more treatment of COX2i (RA: 60.9%, OA: 50.2%) compared to ns-NSAID. 
Interestingly, as patients get more numbers of GI risk factors, there seemed to get 
more proportions of ns-NSAIDs users in both RA and OA patients. cOnclusiOns: 
The proportion of GI risk factors found in OA patients was comparable to that 
in RA patients. There was a tendency to show preferential ns-NSAID treatment 
pattern rather than COX2i especially in the presence of multiple GI risk factors 
in arthritis patients.
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